1433280-00-2

Upstream product

• 364750-81-2 N-tert-Butyloxycarbonyl-(2S,4S)-4-methylproline 
• 1250939-45-7 (2S,4S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1433279-99-2 ((S)-1-{(2S,4S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 73183-34-3 bis(pinacol)diborane 
• 1433279-99-2 ((S)-1-{(2S,4S)-2-[5-(4-bromophenyl)-1H-imidazol-2-yl]-4-methylpyrrolidine-1-carbonyl}-2-methylpropyl)carbamic acid methyl ester 
• 1250939-42-4 (2-(2-(4-bromophenyl)-2-oxoethyl)) 1-(tert-butyl) (2S,4S)-4-methylpyrrolidine-1,2-dicarboxylate 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 72-18-4 L-valine 

Downstream Products

• 1477816-25-3 ((S)-1-{(2S,4S)-2-[4-(5'-chloro-4'-{[4-((S)-2-methylpiperazin-1-yl)piperidine-1-carbonyl]amino}-2'-trifluoromethoxybiphenyl-4-yl)-1H-imidazol-2-yl]-4-methylpyrrolidine-1-carbonyl}-2-methylpropyl)carbamic acid methyl ester 
• 1612854-45-1 C₃₅H₄₁F₃N₄O₆S 
• 1612854-49-5 C₅₄H₆₆N₈O₇ 
• 1433281-07-2 (R)-4-[5-(5-fluoro-4'-{2-[(2S,4S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION

A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.

PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.